Concepedia

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

Jae‐Lyun Lee, Inkeun Park, Kwonoh Park, Seongjoon Park, Yongcheol Ahn, Jin‐Hee Ahn, Tae‐Won Kim, Shin Ahn, Cheryn Song, Jun Hyuk Hong,

Journal of Cancer Research and Clinical Oncology · 2012 · 25 citations · 23 references

Open access

Concepts

MedicineOncologyPharmacologyMetastasisMolecular OncologyTumor ProgressionAngiogenesisKidney CancerMetastatic Disease TreatmentRenal Cell CarcinomaRenal NeoplasmsTyrosine Kinase InhibitorsMetastatic Renal Cell Carcinoma TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVascular Endothelial Growth Factor Receptors

References

23

Global cancer statistics

Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Global Cancer Statistics, 2002

Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

Medicine, Nephrology, Oncology +11